ATYR
aTYR PHARMA INC
NASDAQ · Healthcare · Biotechnology · US
$0.37
−2.18%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +12.7%
- EBIT
- +8.8%
- EPS
- +22.5%
- Free cash flow
- +1.5%
- Operating cash flow
- +1.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +46.4%
- EPS
- +38.0%
Three-year CAGR
- Revenue
- -73.7%
- EBITDA
- -16.1%
- EBIT
- -14.3%
- Net income
- -15.8%
- EPS
- +7.0%
- Free cash flow
- +10.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026